{
    "eid": "2-s2.0-85140749041",
    "title": "Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine",
    "cover-date": "2022-10-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "booster vaccine",
        "cancer",
        "ChAdOx1",
        "CoronaVac",
        "COVID-19 vaccine",
        "heterologous primary vaccination",
        "immunogenicity",
        "omicron",
        "SARS-CoV-2",
        "third dose vaccine"
    ],
    "authors": [
        "Sutima Luangdilok",
        "Passakorn Wanchaijiraboon",
        "Nussara Pakvisal",
        "Thiti Susiriwatananont",
        "Nicha Zungsontiporn",
        "Virote Sriuranpong",
        "Panot Sainamthip",
        "Nungruthai Suntronwong",
        "Preeyaporn Vichaiwattana",
        "Nasamon Wanlapakorn",
        "Yong Poovorawan",
        "Nattaya Teeyapun",
        "Suebpong Tanasanvimon"
    ],
    "citedby-count": 4,
    "ref-count": 35,
    "ref-list": [
        "Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data",
        "Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited",
        "Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group",
        "Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: A systematic review and meta-analysis",
        "Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults\u2014Nine States, January-September 2021",
        "Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study",
        "Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs",
        "Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: Test-negative design studies from British Columbia and Quebec, Canada",
        "Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021",
        "Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination",
        "Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination",
        "Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: A prospective cohort study",
        "The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine",
        "Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar",
        "Waning Immunity after the BNT162b2 Vaccine in Israel",
        "COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant",
        "Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination",
        "The REDCap consortium: Building an international community of software platform partners",
        "Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support",
        "Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination",
        "Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient",
        "Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies",
        "Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients",
        "Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer",
        "High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers",
        "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",
        "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine",
        "SARS-CoV-2 Vaccines",
        "Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine",
        "Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant",
        "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chanthaburi",
            "@id": "112453702",
            "affilname": "Phrapokklao Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/112453702",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulalongkorn Medical Oncology Research Fund",
        "Thai Red Cross Society",
        "King Chulalongkorn Memorial Hospital"
    ]
}